サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：抗ウイルス剤の世界市場（2022年～2028年）
市場調査レポート
商品コード
1215701

抗ウイルス剤の世界市場（2022年～2028年）

Anti-Viral Drug Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
抗ウイルス剤の世界市場（2022年～2028年）
出版日: 2023年01月14日
発行: Orion Market Research
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗ウイルス剤の市場規模は、予測期間中に4.0%のCAGRで成長すると予測されています。

感染症の流行が増加したことで、需要も生産もより幅広いレベルで急増しています。また、製薬会社による継続的な研究開発と新薬開発への投資が、市場成長の新たな可能性を広げています。さらに、ウイルス感染症治療のための薬剤のFDA承認の高まりも、市場開発の突出した側面の1つと考えられています。

当レポートでは、世界の抗ウイルス剤市場について調査分析し、市場概要、セグメント・地域別の市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
  • ポーターの分析

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • 主要戦略分析

第4章 市場内訳

  • 世界の抗ウイルス剤市場：タイプ別
    • ジェネリック
    • ブランド
  • 世界の抗ウイルス剤市場：作用機序別
    • ヌクレオチドポリメラーゼ阻害剤
    • 逆転写酵素阻害剤
    • プロテアーゼ阻害剤
    • その他
  • 世界の抗ウイルス剤市場：用途別
    • HIV
    • 肝炎
    • ヘルペスウイルス
    • インフルエンザ
    • その他

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • その他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第6章 企業プロファイル

  • AbbVie, Inc.
  • Abbott Laboratories
  • Arbutus Biopharma Corp.
  • Aurobindo Pharma, Ltd.
  • BioCryst Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Co.
  • Candel Therapeutics, Inc.
  • Cipla, Inc.
  • Dr. Reddy's Laboratories, Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer, Inc.
  • Sanofi S.A.
  • Sino Biopharmaceutical, Ltd.
  • The Hep B Company
  • Zydus Lifesciences, Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL GENERIC ANTI-VIRAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL BRANDED ANTI-VIRAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 5. GLOBAL ANTI-VIRAL DRUG IN HIV MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL ANTI-VIRAL DRUG IN HEPATITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL ANTI-VIRAL DRUG IN HERPES VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL ANTI-VIRAL DRUG IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 11. GLOBAL NUCLEOTIDE POLYMERASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL PROTEASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL OTHER MECHANISM OF ACTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 19. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 21. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 23. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 24. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 25. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 27. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 29. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 31. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY MECHANISM OF ACTION, 2021 VS 2028 (%)
  • 3. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 4. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL GENERIC ANTI-VIRAL DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL BRANDED ANTI-VIRAL DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL ANTI-VIRAL DRUG IN HIV MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 8. GLOBAL ANTI-VIRAL DRUG IN HEPATITIS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 9. GLOBAL ANTI-VIRAL DRUG IN HERPES VIRUS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 10. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 11. GLOBAL ANTI-VIRAL DRUG IN OTHER APPLICATIONS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 12. GLOBAL NUCLEOTIDE POLYMERASE INHIBITOR MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 13. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 14. GLOBAL PROTEASE INHIBITORS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 15. GLOBAL OTHER MECHANISM OF ACTION MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 16. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 17. US ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. CANADA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. UK ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. FRANCE ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. GERMANY ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. ITALY ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. SPAIN ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. REST OF EUROPE ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. INDIA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. CHINA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. JAPAN ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. SOUTH KOREA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. REST OF ASIA-PACIFIC ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026757

Title:Global Anti-Viral Drug Market Size, Share, and Trends Analysis Report, by Type (Generic Anti-Viral Drugs and Branded Anti-Viral Drugs), by Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), by Application (HIV, Hepatitis, Herpes Virus, Influenza, and Others), Forecast Period (2022-2028).

The global anti-viral drug market is anticipated to grow at a CAGR of 4.0% during the forecast period. The anti-viral drugs have found their effective use in the treatment of viral infections, such as hepatitis, HIV, influenza, and others. The increased prevalence of these infections has surged both the demand as well as production on a wider level. Continuous R&D and investment by pharma companies in new drug development are opening a new path for market growth. Rising FDA approvals of the drug for the treatment of viral infection are also considered one of the prominent aspects of market development. For instance, in March 2022, GlaxoSmithKline Plc and Vir Biotechnology, Inc got approval from the USFDA for the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody due to Omicron BA.2 Subvariant. Moreover, in November 2019, the USFDA approved a supplemental New Drug Application for Roche's Xofluza for the treatment of influenza in patients 12 years of age and older. Likewise, in March 2019, GlaxoSmithKline Plc received approval from the National Medical Products Administration for Viread (tenofovir disoproxil fumarate), an oral antiviral drug for chronic hepatitis B treatment.

The global anti-viral drug market is segmented based on type, mechanism of action, and application. Based on type, the market is sub-segmented into generic anti-viral drugs and branded anti-viral drugs. Based on the mechanism of action, the market is further classified into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Similarly, based on application, it is classified into HIV, hepatitis, herpes virus, influenza, and others.

Geographically, the anti-viral drug market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific region is anticipated to exhibit a high CAGR during the forthcoming period. Growth is attributable to the frequent outbursts of viral diseases, namely, swine flu, dengue, and Ebola in emerging economies. The increasing number of generic pharmaceutical companies present in this region would contribute to the growth. Moreover, the increasing incidence of viral infection and surging approval and expected commercialization of novel medicines for viral infections are the crucial factors anticipated to drive the North American anti-viral drug market growth during the forecast period.

The major market players in the global anti-viral drug market include AbbVie, Inc., Merck & Co., GlaxoSmithKline plc, Pfizer Inc., Mylan NV, Dr. Reddy's Laboratories Ltd., Apotex Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals Ltd., Strides Pharma Science Ltd., Upsher-Smith Laboratories, among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global anti-viral drug is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Anti-Viral Drug Research and Analysis by Type
  • Global Anti-Viral Drug Research and Analysis by Mechanism of Action
  • Global Anti-Viral Drug Research and Analysis by Application

The Report Covers:

  • Comprehensive research methodology of the global anti-viral drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global anti-viral drug market.
  • Insights about market determinants that are stimulating the global anti-viral drug market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Porter's Analysis

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Anti-Viral Drug Market by Type
    • 4.1.1. Generic Anti-Viral Drugs
    • 4.1.2. Branded Anti-Viral Drugs
  • 4.2. Global Anti-Viral Drug Market by Mechanism of Action
    • 4.2.1. Nucleotide Polymerase Inhibitor
    • 4.2.2. Reverse Transcriptase Inhibitors
    • 4.2.3. Protease Inhibitors
    • 4.2.4. Others
  • 4.3. Global Anti-Viral Drug Market by Application
    • 4.3.1. HIV
    • 4.3.2. Hepatitis
    • 4.3.3. Herpes Virus
    • 4.3.4. Influenza
    • 4.3.5. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. AbbVie, Inc.
  • 6.2. Abbott Laboratories
  • 6.3. Arbutus Biopharma Corp.
  • 6.4. Aurobindo Pharma, Ltd.
  • 6.5. BioCryst Pharmaceuticals, Inc.
  • 6.6. Bristol-Myers Squibb Co.
  • 6.7. Candel Therapeutics, Inc.
  • 6.8. Cipla, Inc.
  • 6.9. Dr. Reddy's Laboratories, Ltd.
  • 6.10. F. Hoffmann-La Roche AG
  • 6.11. Gilead Sciences, Inc.
  • 6.12. GlaxoSmithKline PLC
  • 6.13. Johnson & Johnson Services, Inc.
  • 6.14. Merck & Co., Inc.
  • 6.15. Mylan N.V.
  • 6.16. Pfizer, Inc.
  • 6.17. Sanofi S.A.
  • 6.18. Sino Biopharmaceutical, Ltd.
  • 6.19. The Hep B Company
  • 6.20. Zydus Lifesciences, Ltd.